Form 4 for EXEL EXELIXIS, INC.
Accepted 2021-07-23 00:00:00 ET · period of report 2021-07-21 · accession 0000939767-21-000073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-23 | 2021-07-21 | EXEL | Schwab Gisela | Pres, CMO, Prod Dev, Med Aff | M - OptEx | $4.20 | +35.0K | 649.1K | +6% | +$147.0K |
| D | 2021-07-23 | 2021-07-21 | EXEL | Schwab Gisela | Pres, CMO, Prod Dev, Med Aff | M - OptEx | $0.00 | -35.0K | 40.0K | -47% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-21 | M | A | 35,000 | $4.20 | 649,078 | D | — | — | (F1) Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 2 | Derivative | Option (right to buy) | 2021-07-21 | M | D | 35,000 | $0.00 | 40,000 | D | $4.20 · 2017-02-11 to 2023-02-10 | 35,000 Common Stock | (F3) The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |